Inflammation, statin therapy, and long-term mortality in heart failure with preserved ejection fraction: What can we learn from registry data?

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized as a heterogeneous syndrome in which ageing, hypertension, obesity, diabetes, chronic kidney disease, atrial fibrillation, coronary artery disease, and metabolic abnormalities interact with myocardial and vascular dysfunction.Beyond elevated left ventricular filling pressures and impaired relaxation, systemic inflammation, endothelial dysfunction, immune-cell activation, and myocardial fibrosis have emerged as potentially important components of HFpEF pathophysiology [1-3].The study by Stępień et al. [4], based on the Lesser Poland Cracovian Heart Failure Registry (LECRA-HF), adds an interesting perspective by examining whether commonly available immune-inflammatory biomarkers (IIBs) and statin therapy are related to long-term mortality in patients hospitalized with acute HFpEF.The principal finding is that the prognostic value of several inflammatory indices differed according to statin prescription status.